8-K: Pacira BioSciences Reports Mixed Q3 Results Amidst Strategic Shifts and Goodwill Impairment

Pacira BioSciences announced its third quarter 2024 financial results, highlighting revenue growth but also a significant net loss due to a goodwill impairment.

Summary

• Pacira BioSciences reported total revenues of $168.6 million for the third quarter of 2024, compared to $163.9 million in the same period of 2023.
• Net product sales were $132.0 million for EXPAREL, $28.4 million for ZILRETTA, and $5.7 million for iovera.
• The company experienced a net loss of $143.5 million, or $3.11 per share, primarily due to a $163.2 million goodwill impairment.
• Adjusted EBITDA was $54.7 million, compared to $52.9 million in the third quarter of 2023.
• Pacira is reiterating its full-year 2024 financial guidance, projecting total revenue between $680 million and $705 million.
• The company ended the quarter with $453.8 million in cash, cash equivalents, and available-for-sale investments.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with positive revenue growth and strategic advancements offset by a significant net loss and goodwill impairment. The sentiment is cautiously negative due to the financial losses, but there are positive developments that could improve the outlook.

Positives

• Total revenues and EXPAREL sales showed year-over-year growth.
• The company secured a new J-code for EXPAREL, which will enhance reimbursement.
• The final CMS rule for EXPAREL and iovera in outpatient settings will provide additional Medicare reimbursement starting January 1, 2025.
• Pacira is advancing its gene therapy candidate, PCRX-201, with upcoming data presentations.
• Cash provided by operations increased to $53.9 million in Q3 2024 from $44.4 million in Q3 2023.

Negatives

• The company reported a substantial net loss of $143.5 million due to a $163.2 million goodwill impairment.
• Total operating expenses increased significantly to $308.1 million, compared to $146.2 million in the same quarter of 2023.
• ZILRETTA sales experienced a slight decrease compared to the same quarter last year.
• The company's GAAP net income per share was a loss of $3.11.

Risks

• The goodwill impairment indicates a potential overvaluation of assets.
• Increased operating expenses could impact future profitability.
• The company faces competition, including a recently approved generic competitor to EXPAREL.
• The company's stock price has decreased, which may affect investor confidence.
• The company is exposed to risks associated with acquisitions and integration of acquired businesses.

Future Outlook

Pacira is focused on long-term growth and value creation, including investing in its commercial organization and pipeline, with a particular focus on the implementation of separate Medicare reimbursement for EXPAREL in outpatient settings beginning in January 2025. The company is reiterating its full-year 2024 financial guidance.

Management Comments

• Frank D. Lee, chief executive officer of Pacira BioSciences, stated that 2024 continues to be highlighted by important progress across both the clinical pipeline and commercial portfolio.
• Mr. Lee also mentioned that the company intends to build on this momentum by advancing its strategy for long-term growth and value creation.
• Mr. Lee expressed confidence that the investments being made will support and expand the company's leadership in non-opioid pain management.

Industry Context

The announcement comes at a time when there is increasing focus on non-opioid pain management solutions, driven by the opioid crisis. The CMS ruling and new J-code for EXPAREL are positive developments for the company, aligning with broader industry trends towards non-opioid alternatives. The company is also investing in gene therapy, which is an emerging area in the pharmaceutical industry.

Comparison to Industry Standards

• Pacira's revenue growth is modest compared to some high-growth biotech companies, but it is a leader in the non-opioid pain management space.
• The goodwill impairment is a significant negative, suggesting potential issues with past acquisitions or asset valuations, which is not uncommon in the biotech industry.
• The company's focus on securing reimbursement codes and expanding into outpatient settings is a common strategy among pharmaceutical companies.
• The development of PCRX-201 aligns with the industry trend of exploring gene therapies for chronic conditions, similar to companies like Vertex Pharmaceuticals and BioMarin Pharmaceutical.
• The company's adjusted EBITDA is positive, but the net loss highlights the challenges of balancing growth with profitability, a common issue for biotech companies in the development stage.

Management Changes

Stakeholder Impact

• Shareholders will be negatively impacted by the net loss and goodwill impairment.
• Employees may be affected by the restructuring plan.
• Customers will benefit from the continued availability of non-opioid pain management therapies.
• Suppliers may see changes in demand based on the company's strategic shifts.
• Creditors will be monitoring the company's financial performance.

Next Steps

• The company will focus on commercial readiness for the implementation of separate Medicare reimbursement for EXPAREL in outpatient settings beginning in January 2025.
• Pacira will present two-year safety and efficacy data for PCRX-201 at the ACR Converge meeting on November 17, 2024.
• The company will continue to invest in its commercial organization and pipeline.

Key Dates

Keywords

Pacira BioSciences, EXPAREL, ZILRETTA, iovera, Non-opioid pain management, Goodwill impairment, Financial results, Medicare reimbursement, PCRX-201, J-code, EBITDA